<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Renal Inj Prev</journal-id><journal-id journal-id-type="iso-abbrev">J Renal Inj Prev</journal-id><journal-id journal-id-type="publisher-id">J Renal Inj Prev</journal-id><journal-id journal-id-type="publisher-id">JRIP</journal-id><journal-title-group><journal-title>Journal of Renal Injury Prevention</journal-title></journal-title-group><issn pub-type="epub">2345-2781</issn><publisher><publisher-name>Nickan Research Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27689115</article-id><article-id pub-id-type="pmc">5040005</article-id><article-id pub-id-type="doi">10.15171/jrip.2016.34</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original</subject></subj-group></article-categories><title-group><article-title>The effect of lactulose supplementation on fecal microflora of patients with chronic kidney disease; a randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tayebi-Khosroshahi</surname><given-names>Hamid</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Habibzadeh</surname><given-names>Afshin</given-names></name><xref ref-type="aff" rid="A02">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Niknafs</surname><given-names>Bahram</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ghotaslou</surname><given-names>Reza</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yeganeh Sefidan</surname><given-names>Fatemeh</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ghojazadeh</surname><given-names>Morteza</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Moghaddaszadeh</surname><given-names>Majid</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Parkhide</surname><given-names>Sahar</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="A01"><sup>1</sup>Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
</aff><aff id="A02"><sup>2</sup>Medical Education Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
</aff><author-notes><corresp id="COR1"><label>*</label><bold>Corresponding author:</bold> Bahram Niknafs, <email>bahramniknafs@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>29</day><month>7</month><year>2016</year></pub-date><volume>5</volume><issue>3</issue><fpage>162</fpage><lpage>167</lpage><history><date date-type="received"><day>12</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 The Author(s); Published by Nickan Research Institute</copyright-statement><copyright-year>2016</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/" license-type="open-access"><license-p><!--CREATIVE COMMONS-->
This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
</license-p></license></permissions><self-uri xlink:href="http://journalrip.com">http://journalrip.com</self-uri><abstract><p>
<bold>Introduction:</bold> Lactulose is a prebiotic with bifidogenic and urea reduction effects. It can improve Bifidobacteria and Lactobacilli counts in healthy humans and it may possibly have similar effects in chronic kidney disease (CKD) patients.
</p><p>
<bold>Objectives:</bold> To investigate the effect of lactulose on fecal microflora of patients with CKD.
</p><p>
<bold>Patients and Methods:</bold> Thirty-two patients with stages 3 and 4 of CKD (43.8% male with mean age of 58.09&#x000b1;12.75 years) were randomly assigned to intervention (n=16) and control (n=16) groups. Patients in intervention group received 30 mm lactulose syrup three times a day for an 8-week period. Control group received placebo 30 mm three times a day. A fecal sample was obtained from all patients at the beginning and at the end of the study and Bifidobacteria and Lactobacilli was counted.
</p><p>
<bold>Results:</bold> Creatinine (Cr) significantly decreased in intervention group (3.90&#x000b1;1.43 to 3.60&#x000b1;1.44, <italic>P</italic>=0.003) and increased in control group (3.87&#x000b1;2.08 to 4.11&#x000b1;1.99, <italic>P</italic>=0.03). Although Bifidobacterial and Lactobacilli counts were similar before intervention, they were significantly higher at the end of the study in lactulose group (<italic>P</italic>=0.01 and <italic>P</italic>=0.04, respectively). Lactulose led to significant increase in fecal Bifidobacterial counts (3.61&#x000b1;0.54 to 4.90&#x000b1;0.96, <italic>P</italic>&#x0003c;0.001) and Lactobacilli counts (2.79&#x000b1;1.00 to 3.87&#x000b1;1.13, <italic>P</italic>&#x0003c;0.001), while the change in placebo group was not significant.
</p><p>
<bold>Conclusion:</bold> Lactulose administration will increase Bifidobacteria and Lactobacillus counts in patients with CKD.
</p></abstract><kwd-group><kwd>Chronic kidney disease</kwd><kwd>Lactulose</kwd><kwd>Fecal microflora</kwd><kwd>Bifidobacteria</kwd><kwd>Lactobacilli</kwd></kwd-group><counts><table-count count="3"/><ref-count count="37"/><page-count count="6"/></counts></article-meta><notes><p>
<italic>Please cite this paper as:</italic> Tayebi-Khosroshahi H, Habibzadeh A, Niknafs B, Ghotaslou R, Yeganeh Sefidan F, Ghojazadeh M, et al. The effect of lactulose supplementation on fecal microflora of patients with chronic kidney disease; a randomized clinical trial. 2016;5(3):162-167. DOI: 10.15171/jrip.2016.34
</p></notes></front><body><boxed-text position="float" id="bt1" orientation="portrait"><sec id="key1"><title>Implication for health policy/practice/research/medical education:</title><p>Lactulose as a prebiotic can improve Bifidobacteria and Lactobacilli counts. The aim is the evaluation of lactulose on intestinal flora of chronic kidney disease patients. We used lactulose and compared the bifidobacteria and lactobacillus colony counts and also nitrogenous waste products with control patients. There was significant reduction of urea, creatinine in improvement of Bifidobacteria and Lactobacillus counts.</p></sec></boxed-text><sec sec-type="introduction" id="s1"><title>Introduction</title><p>
In the last decades, considerable efforts have been directed at improving human (as well as animal) health or preventing disease by the use of functional foods to which prebiotics and probiotics belong (<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>). Prebiotics are non-digestible and selectively fermented food ingredients that modulates beneficial gastrointestinal microflora, both in the composition and/or their activities, thus generating benefits to human health. Lactobacilli and Bifidobacteria are the usual target genera for prebiotics (<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref>). Numerous scientists investigated the health-promoting effect of prebiotics like indigestible sugars, e.g. fructooligosaccharides, inulin and lactulose (<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref>).
</p><p>
The positive effects of lactulose on colonic metabolism in human is well known (<xref rid="R7" ref-type="bibr">7</xref>). Lactulose is a commercially available disaccharide that is used as a drug in the treatment of hepatic encephalopathy and chronic constipation (<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref>), which has been shown to stimulate the growth of Bifidobacteria (<xref rid="R10" ref-type="bibr">10</xref>).
</p><p>
Uremia is an illness that accompanies&#x000a0;renal failure and chronic kidney disease (CKD). Uremic illness is considered to be due largely to the accumulation of organic waste products that are normally cleared by the renal. However, uremic products are also generated in the gastrointestinal tract (GIT). Toxins generated in, or introduced into the body via the intestine, like advanced glycation end products, phenols, and indoles, all may contribute to the pathogenesis of CKD. Another problem in CKD patients is the prolonged colonic transit time that promotes uremia retention and absorption. It is supposed that prebiotics&#x000a0;like lactulose have a therapeutic role in maintaining a metabolically balanced GIT with increased beneficial GIT microflora, and would reduce progression of CKD and associated uremia (<xref rid="R11" ref-type="bibr">11</xref>-<xref rid="R13" ref-type="bibr">13</xref>). In CKD, lactulose could promote fecal excretion of water, sodium, potassium, ammonium, urea, creatinine (Cr) and protons (<xref rid="R14" ref-type="bibr">14</xref>). In our previous study, we showed that lactulose administration in CKD patients could decrease levels of various deleterious elements, especially nitrogen products (<xref rid="R15" ref-type="bibr">15</xref>).
</p><p>
Due to the role of lactulose as a prebiotics in GIT and its possible positive effects on CKD patients, we aim to evaluate the effects of lactulose supplementation on fecal microflora in these patients.
</p></sec><sec sec-type="patients and methods" id="s2"><title>Patients and Methods</title><sec id="s2-0-1"><title>
Study population
</title><p>
In this randomized controlled clinical trial, 32 patients with CKD in the stages 3 and 4 were recruited and randomly assigned to intervention (n=16) and control (n=16) groups. During the study no patients were excluded or withdrawn in any groups (<xref ref-type="fig" rid="F1">Figure 1</xref>). Patients over 18 years old with an estimated glomerular filtration rate (eGFR) &#x02264;60 ml/min/1.73 m<sup>2</sup> and stages 3 and 4 of CKD, with no history of gastrointestinal or metabolic disease or previous surgery (apart from appendectomy), and without antibiotic treatment or any other medical treatment influencing intestinal microbiota especially probiotics, prebiotics and symbiotics during the 3 months before the start of the study were included. Subjects were advised to maintain their usual diet during the study period and to avoid the intake of fermented milk products and food components containing high quantities of fermentable carbohydrates. The treatment would be stopped if any major complications would have happened and if any patient had diarrhea due to lactulose use, the treatment would be stopped and after a period start with lower dosage. Those could not keep up with the study protocol or with drug intolerance were excluded. The subjects did not have to restrict their everyday diet, medication or daily activities. Those drugs which induce constipation such as AST-120, polystyrene sulfonate and potassium binders were not administered.
</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><graphic xlink:href="jrip-5-162-g001"/><statement><p>Patients who allocated to receive lactulose and control group.</p></statement></fig></sec><sec id="s2-0-2"><title>
Study protocol
</title><p>
The study was conducted over an 8-week period. Patients in case group received 30 mm lactulose syrup (Zahravi Co, Tabriz, Iran) three times a day. The doses administered were chosen based on therapeutic recommendations for CKD patients in a way that subjects did not suffer from negative effects or discomfort. Control group received placebo 30 mm three times a day. All patients were visited weekly in order to evaluate the possible side effects and assessing their adherence to medication. The same company prepared a placebo solution with the same color and taste.
</p></sec><sec id="s2-0-3"><title>
Fecal analysis
</title><p>
A fecal sample was obtained from all patients at the beginning and the end of the study. They were collected in plastic containers under anaerobic conditions, immediately stored at 4&#x000b0;C and analyzed within 3 hours. Stool samples were homogenized with a high-speed blender and serially diluted 10-fold in solution for anaerobes (saline, glucose and cysteine). A volume of 100 mL of each dilution was inoculated in appropriate agars. Bifidobacteria and Lactobacilli were cultured for respectively 5 and 3 days at 37&#x000b0;C in anaerobic conditions (Gas Pak A system, BBL, Cockeysville, MD, USA) with Anaerocult A. Bifidobacteria were counted on the Beerens medium (Beerens, 1991); Lactobacilli were counted on the Rogosa medium.
</p></sec><sec id="s2-0-4"><title>
Ethical issues
</title><p>
The research followed the tenets of the Declaration of Helsinki. Informed consents were obtained from parents and the research was approved by the Ethics Committee of Tabriz University of Medical Sciences. This clinical trial had a registration ID: IRCT201105302858N2 in Iran (<uri xlink:href="http://www.irct.ir/">http://www.irct.ir/</uri>).
</p></sec><sec id="s2-0-5"><title>
Statistical analysis
</title><p>
Statistical analyses were performed using the SPSS version 16.0 (SPSS Inc., Chicago, Illinois). Faecal concentrations of bacteria were expressed as log colony forming unit (CFU)/g wet weight. Continuous values were expressed as mean &#x000b1; stan&#x000ad;dard deviation (SD) and categorical variables were expressed as percentages. The categorical parameters were compared by &#x003c7;<sup>2</sup> tests or Fisher&#x02019;s exact test. The continuous variables before and after intervention between groups was compared with independent <italic>t</italic> test and within each group was compared with paired samples <italic>t</italic> test. A <italic>P</italic> value less than 0.05 was considered significant.
</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>
Thirty-two CKD patients (18 female with mean age of 58.09 &#x000b1; 12.75 years) were divided into intervention (n=16) and control (n=16) groups. Patients&#x02019; baseline findings are demonstrated in <xref ref-type="table" rid="T1">Table 1</xref>. There was no difference in baseline findings between groups.
</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>
Patients&#x02019; baseline findings
</title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 0px 0px 1pt 0px ; border-style: none none solid none"><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
<bold>Intervention</bold>
</td><td rowspan="1" colspan="1">
<bold>Control</bold>
</td><td rowspan="1" colspan="1">
<italic><bold>P</bold></italic>
<bold> value</bold>
</td></tr><tr style="background-color:#e6f0fa"><td rowspan="1" colspan="1">Age (y)</td><td rowspan="1" colspan="1">59.31 &#x000b1; 12.97</td><td rowspan="1" colspan="1">56.88 &#x000b1; 12.84</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Gender, male, n (%)</td><td rowspan="1" colspan="1">9 (56.3%)</td><td rowspan="1" colspan="1">5 (31.3%)</td><td rowspan="1" colspan="1">NS</td></tr><tr style="background-color:#e6f0fa"><td rowspan="1" colspan="1">Etiology of CKD</td><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">
</td></tr><tr style="background-color:#e6f0fa"><td rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">
</td></tr><tr><td rowspan="1" colspan="1">Glomerulonephritis</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
</td></tr><tr style="background-color:#e6f0fa"><td rowspan="1" colspan="1">Polycystic kidney disease</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">
</td></tr><tr><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>
Abbreviations: CKD, Chronic kidney disease; NS: not significant
</p></fn></table-wrap-foot></table-wrap><p>
<xref ref-type="table" rid="T2">Table 2</xref> demonstrates the laboratory findings before and after intervention in both groups. There were no significant differences between groups in hemoglobin (Hb), Cr and blood urea nitrogen (BUN) before and at the end of the study. Comparing the results before and at the end of the study within each group, we observed that Cr significantly decreased in intervention group (from 3.90&#x000b1;1.43 to 3.60&#x000b1;1.44, <italic>P</italic>=0.003). In control group receiving placebo, Hb was significantly decreased (from 11.080.82 to 10.93&#x000b1;0.92, <italic>P</italic>=0.02) and Cr was significantly increased (from 3.87&#x000b1;2.08 to 4.11&#x000b1;1.99, <italic>P</italic>=0.03). The percentage of change in Cr level during the trial was calculated and showed that in intervention group Cr was decreased while it was increased in control group and the difference was significant (-8.01&#x000b1;2.40 versus 10.20&#x000b1;4.94; <italic>P</italic>=0.002).
</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>
Laboratory findings before and after intervention in both groups
</title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 0px 0px 1pt 0px ; border-style: none none solid none"><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
<bold>Intervention</bold>
</td><td rowspan="1" colspan="1">
<bold>Control</bold>
</td><td rowspan="1" colspan="1">
<italic><bold>P</bold></italic>
<bold> value</bold>
</td></tr><tr style="background-color:#e6f0fa"><td rowspan="1" colspan="1">Hb (g/dL)</td><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
</td></tr><tr><td rowspan="1" colspan="1">Before</td><td rowspan="1" colspan="1">11.00 &#x000b1; 1.36</td><td rowspan="1" colspan="1">11.08 &#x000b1; 0.82</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">At the end</td><td rowspan="1" colspan="1">11.16 &#x000b1; 1.19</td><td rowspan="1" colspan="1">10.93 &#x000b1; 0.92</td><td rowspan="1" colspan="1">NS</td></tr><tr style="background-color:#e6f0fa"><td rowspan="1" colspan="1">Cr (mg/dL)</td><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
</td></tr><tr><td rowspan="1" colspan="1">Before</td><td rowspan="1" colspan="1">3.90 &#x000b1; 1.43</td><td rowspan="1" colspan="1">3.87 &#x000b1; 2.08</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">At the end</td><td rowspan="1" colspan="1">3.60 &#x000b1; 1.44</td><td rowspan="1" colspan="1">4.11 &#x000b1; 1.99</td><td rowspan="1" colspan="1">NS</td></tr><tr style="background-color:#e6f0fa"><td rowspan="1" colspan="1">BUN (mg/dL)</td><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
</td></tr><tr><td rowspan="1" colspan="1">Before</td><td rowspan="1" colspan="1">55.31 &#x000b1; 14.54</td><td rowspan="1" colspan="1">53.88 &#x000b1; 14.68</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">At the end</td><td rowspan="1" colspan="1">48.38 &#x000b1; 15.54</td><td rowspan="1" colspan="1">55.38 &#x000b1; 11.98</td><td rowspan="1" colspan="1">NS</td></tr></tbody></table></table-wrap><p>
<xref ref-type="table" rid="T3">Table 3</xref> demonstrates the effect of 8-week ingestion of lactulose or placebo (30 mL/d) on the fecal bacterial counts in CKD patients. Before intervention, there were no significant differences between groups in fecal Bifidobacterial counts and Lactobacilli counts. At the end of the study, fecal Bifidobacterial counts and Lactobacilli counts were significantly higher after lactulose consumption compared to placebo ingestion. Lactulose led to significant increase in fecal Bifidobacterial counts (<italic>P</italic>&#x0003c;0.001) and Lactobacilli counts (<italic>P</italic>&#x0003c;0.001). Placebo consumption in control group did not lead to any significant fecal Bifidobacterial (<italic>P</italic>=0.13) or Lactobacilli (<italic>P</italic>=0.15) count change.
</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>
Effect of 8-week ingestion of lactulose or placebo (30 mL, three times a day) on the fecal bacterial counts (mean &#x000b1; SD; log CFU/g) in CKD patients
</title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 0px 0px 1pt 0px ; border-style: none none solid none"><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
<bold>Intervention</bold>
</td><td rowspan="1" colspan="1">
<bold>Control</bold>
</td><td rowspan="1" colspan="1">
<italic><bold>P</bold></italic>
<bold> value</bold>
</td></tr><tr style="background-color:#e6f0fa"><td rowspan="1" colspan="1">Bifidobacterial counts (log CFU/g)</td><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
</td></tr><tr><td rowspan="1" colspan="1">Before</td><td rowspan="1" colspan="1">3.61 &#x000b1; 0.54</td><td rowspan="1" colspan="1">3.81 &#x000b1; 0.70</td><td rowspan="1" colspan="1">0.37</td></tr><tr><td rowspan="1" colspan="1">At the end</td><td rowspan="1" colspan="1">4.90 &#x000b1; 0.96</td><td rowspan="1" colspan="1">4.03 &#x000b1; 0.90</td><td rowspan="1" colspan="1">
0.01<sup>a</sup>
</td></tr><tr style="background-color:#e6f0fa"><td rowspan="1" colspan="1">Lactobacilli counts (log CFU/g)</td><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
</td></tr><tr><td rowspan="1" colspan="1">Before</td><td rowspan="1" colspan="1">2.79 &#x000b1; 1.00</td><td rowspan="1" colspan="1">3.14 &#x000b1; 1.28</td><td rowspan="1" colspan="1">0.39</td></tr><tr><td rowspan="1" colspan="1">At the end</td><td rowspan="1" colspan="1">3.87 &#x000b1; 1.13</td><td rowspan="1" colspan="1">3.04 &#x000b1; 1.14</td><td rowspan="1" colspan="1">
0.04<sup>a</sup>
</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>a</sup>
<italic>P</italic> is two sided significant.
</p></fn></table-wrap-foot></table-wrap><p>
There were not any considerable side effects regarding lactulose use.
</p></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>
In this randomized clinical trial we evaluated the effects of lactulose on fecal microflora in CKD patients and observed significant increase in fecal bifidobacterial and lactobacillus count in patients receiving lactulose, which showed no difference in placebo group.
</p><p>
There are no studies evaluating lactulose effects on GIT microflora in CKD patients. Previous studies on healthy humans have shown significant increase in fecal bifidobacteria counts in healthy and even in cirrhotic patients and those with idiopathic constipation (<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref>). However, unlike our findings, none of these studies could show any significant changes in lactobacillus counts. It is shown in other prebiotics except lactulose that Lactobacilli count significantly increases after prebiotic administration (<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref>). In contrast to aforementioned results, Bouhnik et al (<xref rid="R20" ref-type="bibr">20</xref>) observed that lactulose was not bifidogenic and did not cause significant increase in the bifidobacteria count; however the study was performed on healthy subjects and in duration of 8 days which would affect the results.
</p><p>
Accumulation of urea in the body fluids in humans and animals with renal failure leads to its heavy influx into the GIT (<xref rid="R21" ref-type="bibr">21</xref>), which is compounded by microbial colonization of the upper intestinal tract and dramatic change in the composition of the gut microbiome (<xref rid="R22" ref-type="bibr">22</xref>).This microbial colonization in intestine in CKD patients are mostly due to inefficient protein assimilation in the small intestine resulting in more protein entering the large intestine, prolonged colonic transit time, and increased luminal pH secondary to increased colonic urea diffusion (<xref rid="R11" ref-type="bibr">11</xref>). As well it is demonstrated that colonic microbial activity may contribute to uremic solute production (<xref rid="R23" ref-type="bibr">23</xref>). New studies are aim to find a way to reduce unwanted bacterial colonization by increasing beneficiary microflora including bifidobacteria and lactobacillus. This improvement could produce compounds to inhibit potential pathogens, produce digestive enzymes and reduce blood ammonia levels and constipation (<xref rid="R24" ref-type="bibr">24</xref>).
</p><p>
The prebiotic lactulose has the potential to alter fecal flora (<xref rid="R25" ref-type="bibr">25</xref>). It is neither absorbed nor metabolized in the upper GIT but is degraded to organic acids by bacteria of the proximal colon (<xref rid="R26" ref-type="bibr">26</xref>). Lactulose mostly can act as a substrate for many lactic acid bacteria and increase their amount mostly Bifidobacteria and Lactobacilli. It also decreases significantly the number of (lecithinase-positive) clostridia and Bacteroidaceae decreased (<xref rid="R27" ref-type="bibr">27</xref>). However, we only evaluated the changes in the amount of Bifidobacteria and Lactobacilli.
</p><p>
The low concentrations of Lactobacilli and Bifidobacteria have been shown previously in renal failure patients (<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref>). It is suggested that prebiotic intake may be particularly effective for subjects exhibiting low intrinsic numbers of Bifidobacterial (<xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R31" ref-type="bibr">31</xref>). It is possible that prebiotics like lactulose be also effective in subjects with lower Lactobacilli count. CKD patients in our study had very lower Bifidobacteria and Lactobacilli counts than healthy subjects reported in the literature which was significantly increased after lactulose administration.
</p><p>
Elevated levels of p-cresol have recently been demonstrated to be correlated to a higher mortality in uremic syndrome (<xref rid="R32" ref-type="bibr">32</xref>). The exact pathogenic mechanisms occurring in case of kidney disease are not completely understood today. Therefore, strategies that counteract the accumulation of p-cresol and other protein fermentation metabolites might constitute a significant improvement in the management of those patients. De Preter and colleagues observed a significant reduction of the urinary 15N and p-cresol (as a part of uremic toxins) excretion after the intake of lactulose, which was accompanied by a significant increase in the fecal 15N output (<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref>). These studies indicate that subjects with higher baseline levels of uremic toxins would show a higher response to prebiotic dosing.
</p><p>
The mechanism of increasing bifidobacteria and lactobacillus after lactulose administration is ambiguous. There are two considerable processes. One possibility is lactulose increased directly bifidobacteria and lactobacillus, consequently it declined serum Cr and BUN level. Another is lactulose reduced uremic toxins, so it declined serum Cr and BUN level, consequently it increased bifidobacteria and lactobacillus.
</p><p>
To consider the second possibility, we need to measure uremic toxins. We only evaluated blood levels of BUN and Cr and observed a significant reduction in Cr levels after lactulose administration, which had a significant increase in placebo group. Although not measuring the uremic toxins in our study could be a great limitation to our findings; it could be concluded that lactulose could reduce uremic toxins; however, the exact mechanism and effect should be evaluated using p-cresol and other uremic toxins.
</p><p>
As mentioned, we only observed significant decrease in Cr levels in the intervention group and Cr increase in control group with no significant difference in BUN levels. However, in our previous study, we observed significant decrease in urea and Cr after treatment with lactulose (<xref rid="R15" ref-type="bibr">15</xref>). In another study, Miranda Alatriste and colleagues (<xref rid="R35" ref-type="bibr">35</xref>) only observed 11% reduction in BUN levels of CKD patients on probiotic supplementation. They concluded that lower dosage of supplementation, amount of protein consumption and small sample size can affect the result. It is possible that similar factors have role in the low non-significant decrease of BUN in our study.
</p><p>
We also observed that Hb was maintained in the intervention group while had significantly decreased in the control group. Cetin and colleagues (<xref rid="R36" ref-type="bibr">36</xref>) observed significant increase in RBC counts, Hct and Hb values in the group supplemented with probiotic compared with control. Such increase has also been reported in animal studies (<xref rid="R37" ref-type="bibr">37</xref>). However, in our previous study we observed no significant difference between Hb values before and after treatment (<xref rid="R15" ref-type="bibr">15</xref>).Considering these findings, it is possible that dietary probiotic and prebiotic supplementation such as lactulose may improve Hb levels in normal subjects and even in CKD patients.
</p><p>
This study as the first study evaluating lactulose effects in CKD patients has some strengths and limitations; this is a randomized clinical trial with control group that allowed a better comparison of the results between groups and better evaluation of the lactulose efficacy. As a limitation we did not measure uremic toxins and could not evaluate the exact effects of lactulose on reducing these toxins by influencing the GIT. However, the reduction in the Cr levels and not increase in its values could be the effect of this prebiotic in this regard.
</p></sec><sec sec-type="conclusion" id="s5"><title>Conclusion</title><p>
The results of current study showed that lactulose administration will increase bifidobacteria and lactobacillus counts in patients with CKD. Considering our previous findings regarding the role of lactulose in reducing the uremic toxins, it is possible that increase bifidobacteria and lactobacillus counts can cause reduction of uremic toxins and also the BUN and Cr which would improve the function of the kidney in CKD patients.
</p></sec><sec id="s6"><title>Limitations of the study</title><p>
The limitation of this study was small proportion of patients. Thus we suggest more investigations on this aspect of kidney diseases patients.
</p></sec><sec id="s7"><title>Acknowledgments</title><p>
The authors wish to thank the hemodialysis staffs of Shahid Madani and Imam-Reza hospitals for their continuing efforts.
</p></sec><sec id="s8"><title>Authors&#x02019; contribution</title><p>
HTK and BN conceived the study and contributed reagents and tools. RG and MM performed the study. AH, MG and SP analyzed the data and drafted the final manuscript. All authors read, revised and approved the final manuscript.
</p></sec><sec id="s9"><title>Conflicts of interest</title><p>
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.
</p></sec><sec id="s10"><title>Ethical considerations</title><p>
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by authors.
</p></sec><sec id="s11"><title>Funding/Support</title><p>
This study was extracted from residential thesis of Bahram Niknasfs and financially supported by Tabriz University of Medical Sciences (Grant# 89/3-1/1).
</p></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><name><surname>Roberfroid</surname><given-names>M</given-names></name><name><surname>Gibson</surname><given-names>GR</given-names></name><name><surname>Hoyles</surname><given-names>L</given-names></name><name><surname>McCartney</surname><given-names>AL</given-names></name><name><surname>Rastall</surname><given-names>R</given-names></name><name><surname>Rowland</surname><given-names>I</given-names></name><etal/><article-title>Prebiotic effects: metabolic and health benefits</article-title><source>Br J Nutr</source><year>2010</year><volume>104</volume><fpage>S1</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1017/S0007114510003363</pub-id><pub-id pub-id-type="pmid">20920376</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><name><surname>de Vrese</surname><given-names>M</given-names></name><name><surname>Schrezenmeir</surname><given-names>J</given-names></name><article-title>Probiotics, prebiotics, and synbiotics</article-title><source>Adv Biochem Eng Biotechnol</source><year>2008</year><volume>111</volume><fpage>1</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/10_2008_097</pub-id><pub-id pub-id-type="pmid">18461293</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><name><surname>Gibson</surname><given-names>GR</given-names></name><article-title>Probiotics and prebiotics and their function</article-title><source>Funct Nutr</source><year>2003</year><volume>2</volume><fpage>11</fpage><lpage>3</lpage></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><name><surname>Slavin</surname><given-names>J</given-names></name><article-title>Fiber and prebiotics: in mechanisms and health benefits</article-title><source>Nutrients</source><year>2013</year><volume>5</volume><fpage>1417</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">23609775</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><name><surname>Gibson</surname><given-names>GR</given-names></name><name><surname>Beatty</surname><given-names>ER</given-names></name><name><surname>Wand</surname><given-names>X</given-names></name><name><surname>Cumings</surname><given-names>JH</given-names></name><article-title>Selective stimulation of Bifidobacteria in the human colon by oligofructose and inulin</article-title><source>Gastroenterol</source><year>1995</year><volume>108</volume><fpage>975</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/0016-5085(95)90192-2</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><name><surname>Weber</surname><given-names>FL</given-names></name><article-title>Effects of lactulose on nitrogen metabolism</article-title><source>Scand J Gastroenterol</source><year>1997</year><volume>222</volume><fpage>83</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">27035200</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><name><surname>Bianchi</surname><given-names>G</given-names></name><name><surname>Ronchi</surname><given-names>M</given-names></name><name><surname>Marchedini</surname><given-names>G</given-names></name><article-title>Effects of lactulose on carbohydrate metabolism and diabetes mellitus</article-title><source>Scand J Gastroenterol</source><year>1997</year><volume>222</volume><fpage>62</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">27035195</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><name><surname>Voskuijl</surname><given-names>W</given-names></name><name><surname>de Lorijn</surname><given-names>F</given-names></name><name><surname>Verwijs</surname><given-names>W</given-names></name><name><surname>Hogeman</surname><given-names>P</given-names></name><name><surname>Heijmans</surname><given-names>J</given-names></name><name><surname>M&#x000e4;kel</surname><given-names>W</given-names></name><etal/><article-title>PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial</article-title><source>Gut</source><year>2004</year><volume>53</volume><fpage>1590</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1136/gut.2004.043620</pub-id><pub-id pub-id-type="pmid">15479678</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><name><surname>Patil</surname><given-names>DH</given-names></name><name><surname>Westaby</surname><given-names>D</given-names></name><name><surname>Mahida</surname><given-names>YR</given-names></name><name><surname>Palmer</surname><given-names>KR</given-names></name><name><surname>Rees</surname><given-names>R</given-names></name><name><surname>Clark</surname><given-names>ML</given-names></name><etal/><article-title>Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy</article-title><source>Gut</source><year>1987</year><volume>28</volume><fpage>255</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">3570029</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><name><surname>Tuohy</surname><given-names>KM</given-names></name><name><surname>Ziemer</surname><given-names>CJ</given-names></name><name><surname>Klinder</surname><given-names>A</given-names></name><name><surname>Knobel</surname><given-names>Y</given-names></name><name><surname>Pool-Zobel</surname><given-names>BL</given-names></name><name><surname>Gibson</surname><given-names>GR</given-names></name><article-title>A human volunteer study to determine the prebiotic effects of lactulose powder on human colonic microbiota</article-title><source>Microb Ecol Health Dis</source><year>2002</year><volume>14</volume><fpage>165</fpage><lpage>73</lpage></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><name><surname>Evenepoel</surname><given-names>P</given-names></name><name><surname>Meijers</surname><given-names>BK</given-names></name><name><surname>Bammens</surname><given-names>BR</given-names></name><name><surname>Verbeke</surname><given-names>K</given-names></name><article-title>Uremic toxins originating from colonic microbial metabolism</article-title><source>Kidney Int Suppl</source><year>2009</year><volume>114</volume><fpage>S12</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/ki.2009.402</pub-id><pub-id pub-id-type="pmid">19946322</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><name><surname>Vitetta</surname><given-names>L</given-names></name><name><surname>Gobe</surname><given-names>G</given-names></name><article-title>Uremia and chronic kidney disease: the role of the gut microflora and therapies with pro- and prebiotics</article-title><source>Mol Nutr Food Res</source><year>2013</year><volume>57</volume><fpage>824</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1002/mnfr.201200714</pub-id><pub-id pub-id-type="pmid">23450842</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><name><surname>Vitetta</surname><given-names>L</given-names></name><name><surname>Linnane</surname><given-names>AW</given-names></name><name><surname>Gobe</surname><given-names>GC</given-names></name><article-title>From the gastrointestinal tract (GIT) to the kidneys: live bacterial cultures (probiotics) mediating reductions of uremic toxin levels via free radical signaling</article-title><source>Toxins (Basel)</source><year>2013</year><volume>5</volume><fpage>2042</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.3390/toxins5112042</pub-id><pub-id pub-id-type="pmid">24212182</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><name><surname>Vogt</surname><given-names>B</given-names></name><name><surname>Frey</surname><given-names>FJ</given-names></name><article-title>Lactulose and renal failure</article-title><source>Scand J Gastroenterol Suppl</source><year>1997</year><volume>222</volume><fpage>100</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">9145459</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><name><surname>Tayebi Khosroshahi</surname><given-names>H</given-names></name><name><surname>Habibzadeh</surname><given-names>A</given-names></name><name><surname>Khoshbaten</surname><given-names>M</given-names></name><name><surname>Rahbari</surname><given-names>B</given-names></name><name><surname>Chaichi</surname><given-names>P</given-names></name><name><surname>Badiee</surname><given-names>AH</given-names></name><article-title>Lactulose for reduction of nitrogen products in patients with chronic kidney disease</article-title><source>Iran J Kidney Dis</source><year>2014</year><volume>8</volume><fpage>377</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">25194404</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><name><surname>Bouhnik</surname><given-names>Y</given-names></name><name><surname>Attar</surname><given-names>A</given-names></name><name><surname>Joly</surname><given-names>FA</given-names></name><name><surname>Riottot</surname><given-names>M</given-names></name><name><surname>Dyard</surname><given-names>F</given-names></name><name><surname>Flourie</surname><given-names>B</given-names></name><article-title>Lactulose ingestion increases faecal bifidobacterial counts: A randomized double-blind study in healthy humans</article-title><source>Eur J Clin Nutr</source><year>2004</year><volume>58</volume><fpage>462</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">14985684</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><name><surname>Bouhnik</surname><given-names>Y</given-names></name><name><surname>Neut</surname><given-names>C</given-names></name><name><surname>Raskine</surname><given-names>L</given-names></name><name><surname>Michel</surname><given-names>C</given-names></name><name><surname>Riottot</surname><given-names>M</given-names></name><name><surname>Andrieux</surname><given-names>C</given-names></name><etal/><article-title>Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation</article-title><source>Aliment Pharmacol Ther</source><year>2004</year><volume>19</volume><fpage>889</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2004.01918.x</pub-id><pub-id pub-id-type="pmid">15080850</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><name><surname>Langlands</surname><given-names>SJ</given-names></name><name><surname>Hopkins</surname><given-names>MJ</given-names></name><name><surname>Coleman</surname><given-names>N</given-names></name><name><surname>Cummings</surname><given-names>JH</given-names></name><article-title>Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel</article-title><source>Gut</source><year>2004</year><volume>53</volume><fpage>1610</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1136/gut.2003.037580</pub-id><pub-id pub-id-type="pmid">15479681</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><name><surname>Hijov&#x000e1;</surname><given-names>E</given-names></name><name><surname>Bomba</surname><given-names>A</given-names></name><name><surname>Bertkov&#x000e1;</surname><given-names>I</given-names></name><name><surname>Strojn&#x000fd;</surname><given-names>L</given-names></name><name><surname>Szabadosov&#x000e1;</surname><given-names>V</given-names></name><name><surname>&#x00160;olt&#x000e9;sov&#x000e1;</surname><given-names>A</given-names></name><article-title>Prebiotics and bioactive natural substances induce changes of composition and metabolic activities of the colonic microflora in cancerous rats</article-title><source>Acta Biochim Pol</source><year>2012</year><volume>59</volume><fpage>271</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">22540114</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><name><surname>Bouhnik</surname><given-names>Y</given-names></name><name><surname>Raskine</surname><given-names>L</given-names></name><name><surname>Simoneau</surname><given-names>G</given-names></name><name><surname>Vicaut</surname><given-names>E</given-names></name><name><surname>Neut</surname><given-names>C</given-names></name><name><surname>Flouri&#x000e9;</surname><given-names>B</given-names></name><etal/><article-title>The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study</article-title><source>Am J Clin Nutr</source><year>2004</year><volume>80</volume><fpage>1658</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">15585783</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><name><surname>Lee</surname><given-names>YT</given-names></name><article-title>Urea concentration in intestinal fluids in normal and uremic dogs</article-title><source>J Surg Oncol</source><year>1971</year><volume>3</volume><fpage>163</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">5094276</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><name><surname>Vaziri</surname><given-names>ND</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name><name><surname>Pahl</surname><given-names>MV</given-names></name><name><surname>Piceno</surname><given-names>YM</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>DeSantis</surname><given-names>TZ</given-names></name><etal/><article-title>Chronic kidney disease alters the composition of intestinal microbial flora</article-title><source>Kidney Int</source><year>2013</year><volume>83</volume><fpage>308</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/ki.2012.345</pub-id><pub-id pub-id-type="pmid">22992469</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><name><surname>Aronov</surname><given-names>PA</given-names></name><name><surname>Luo</surname><given-names>FJ</given-names></name><name><surname>Plummer</surname><given-names>NS</given-names></name><name><surname>Quan</surname><given-names>Z</given-names></name><name><surname>Holmes</surname><given-names>S</given-names></name><name><surname>Hostetter</surname><given-names>TH</given-names></name><etal/><article-title>Colonic contribution to uremic solutes</article-title><source>J Am Soc Nephrol</source><year>2011</year><volume>22</volume><fpage>1769</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1681/ASN.2010121220</pub-id><pub-id pub-id-type="pmid">21784895</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><name><surname>Reddy</surname><given-names>BS</given-names></name><article-title>Possible mechanisms by which pro- and prebiotics influence colon carcinogenesis and tumor growth</article-title><source>J Nutr</source><year>1999</year><volume>129</volume><fpage>1478S</fpage><lpage>82S</lpage><pub-id pub-id-type="pmid">10395625</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><name><surname>Battle</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>T</given-names></name><name><surname>Fulton</surname><given-names>J</given-names></name><article-title>Lactulose may help prevent urinary tract infections</article-title><source>BMJ</source><year>2001</year><volume>323</volume><fpage>936</fpage><pub-id pub-id-type="doi">10.1136/bmj.323.7318.936</pub-id><pub-id pub-id-type="pmid">11668146</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><name><surname>Branner</surname><given-names>GR</given-names></name><name><surname>Roth-Maier</surname><given-names>DA</given-names></name><article-title>Influence of pre-, pro-, and synbiotics on the intestinal availability of different B-vitamins</article-title><source>Arch Anim Nutr</source><year>2006</year><volume>60</volume><fpage>191</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1080/17450390600678985</pub-id><pub-id pub-id-type="pmid">16736854</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><name><surname>Terada</surname><given-names>A</given-names></name><name><surname>Hara</surname><given-names>H</given-names></name><name><surname>Kataoka</surname><given-names>M</given-names></name><name><surname>Mitsuoka</surname><given-names>T</given-names></name><name><surname>Shou-Tou</surname><given-names>L</given-names></name><name><surname>Ikegame</surname><given-names>K</given-names></name><etal/><article-title>Lecithinase-positive clostridia isolated from human feces on consumption of lactulose and lactosucrose</article-title><source>Jpn J Food Microbiol</source><year>1994</year><volume>11</volume><fpage>119</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.5803/jsfm.11.119</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><name><surname>Osipov</surname><given-names>MIu</given-names></name><name><surname>Bilev</surname><given-names>AE</given-names></name><name><surname>Osipov</surname><given-names>IuA</given-names></name><article-title>Microbial intestinal biocenosis in lingering and complicated course of community pneumonia</article-title><source>Ter Arkh</source><year>2008</year><volume>80</volume><fpage>52</fpage><lpage>7</lpage><comment>[in Russian].</comment><pub-id pub-id-type="pmid">18372597</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><name><surname>Bobrov</surname><given-names>VA</given-names></name><name><surname>Karpov</surname><given-names>PF</given-names></name><article-title>Microecological disorders in the intestines of patients with chronic kidney failure and the arterial hypertension syndrome</article-title><source>Ter Arkh</source><year>1993</year><volume>65</volume><fpage>41</fpage><lpage>3</lpage><comment>[in Russian].</comment><pub-id pub-id-type="pmid">8378848</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><name><surname>Tuohy</surname><given-names>KM</given-names></name><name><surname>Kolida</surname><given-names>S</given-names></name><name><surname>Lustenberger</surname><given-names>AM</given-names></name><name><surname>Gibson</surname><given-names>GR</given-names></name><article-title>The prebiotic effects of biscuits containing partially hydrolysed guar gum and fructo-oligosaccharides&#x02014;a human volunteer study</article-title><source>Br J Nutr</source><year>2001</year><volume>86</volume><fpage>341</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1079/BJN2001394</pub-id><pub-id pub-id-type="pmid">11570986</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><name><surname>Vanhoutte</surname><given-names>T</given-names></name><name><surname>De Preter</surname><given-names>V</given-names></name><name><surname>De Brandt</surname><given-names>E</given-names></name><name><surname>Verbeke</surname><given-names>K</given-names></name><name><surname>Swings</surname><given-names>J</given-names></name><name><surname>Huys</surname><given-names>G</given-names></name><article-title>Molecular monitoring of the fecal microbiota of healthy human subjects during administration of lactulose and Saccharomyces boulardii</article-title><source>Appl Environ Microbiol</source><year>2006</year><volume>72</volume><fpage>5990</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1128/AEM.00233-06</pub-id><pub-id pub-id-type="pmid">16957220</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><name><surname>Bammens</surname><given-names>B</given-names></name><name><surname>Evenepoel</surname><given-names>P</given-names></name><name><surname>Keuleers</surname><given-names>H</given-names></name><name><surname>Verbeke</surname><given-names>K</given-names></name><name><surname>Vanrentherghem</surname><given-names>Y</given-names></name><article-title>Free serum concentrations of the proteinbound retention solute p-cresol predict mortality in hemodialysis patients</article-title><source>Kidney Int</source><year>2006</year><volume>69</volume><fpage>1081</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5000115</pub-id><pub-id pub-id-type="pmid">16421516</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><name><surname>de Preter</surname><given-names>V</given-names></name><name><surname>Coopmans</surname><given-names>T</given-names></name><name><surname>Rutgeerts</surname><given-names>P</given-names></name><name><surname>Verbeke</surname><given-names>K</given-names></name><article-title>Influence of long-term administration of lactulose and Saccharomyces boulardii on the colonic generation of phenolic compounds in healthy human subjects</article-title><source>J Am Coll Nutr</source><year>2006</year><volume>25</volume><fpage>541</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17229902</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><name><surname>de Preter</surname><given-names>V</given-names></name><name><surname>Vanhoutte</surname><given-names>T</given-names></name><name><surname>Huys</surname><given-names>G</given-names></name><name><surname>Swings</surname><given-names>J</given-names></name><name><surname>Rutgeerts</surname><given-names>P</given-names></name><name><surname>Verbeke</surname><given-names>K</given-names></name><article-title>Baseline microbiota activity and initial bifidobacteria counts influence responses to prebiotic dosing in healthy subjects</article-title><source>Aliment Pharmacol Ther</source><year>2008</year><volume>27</volume><fpage>504</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2007.03588.x</pub-id><pub-id pub-id-type="pmid">18081736</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><name><surname>Miranda Alatriste</surname><given-names>PV</given-names></name><name><surname>Urbina Arronte</surname><given-names>R</given-names></name><name><surname>G&#x000f3;mez Espinosa</surname><given-names>CO</given-names></name><name><surname>Espinosa Cuevas Mde</surname><given-names>L</given-names></name><article-title>Effect of probiotics on human blood urea levels in patients with chronic renal failure</article-title><source>Nutr Hosp</source><year>2014</year><volume>29</volume><fpage>582</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.3305/nh.2014.29.3.7179</pub-id><pub-id pub-id-type="pmid">24559003</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><name><surname>Cetin</surname><given-names>N</given-names></name><name><surname>G&#x000fc;&#x000e7;l&#x000fc;</surname><given-names>BK</given-names></name><name><surname>Cetin</surname><given-names>E</given-names></name><article-title>The effects of probiotic and mannanoligosaccharide on some haematological and immunological parameters in turkeys</article-title><source>J Vet Med A Physiol Pathol Clin Med</source><year>2005</year><volume>52</volume><fpage>263</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/j.1439-0442.2005.00736.x</pub-id><pub-id pub-id-type="pmid">16050905</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><name><surname>Baillon</surname><given-names>ML</given-names></name><name><surname>Marshall-Jones</surname><given-names>ZV</given-names></name><name><surname>Butterwick</surname><given-names>RF</given-names></name><article-title>Effects of probiotic Lactobacillus acidophilus strain DSM13241 in healthy adult dogs</article-title><source>Am J Vet Res</source><year>2004</year><volume>65</volume><fpage>338</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">15027683</pub-id></element-citation></ref></ref-list></back></article>